title: Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
abstract: BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone.
authors.affiliation: State University of New York at Stony Brook, The Rockefeller University, New York, New York, USA.
authors.forename: Roy T
authors.initials: RT
authors.lastname: Steigbigel
authors.forename: David A
authors.initials: DA
authors.lastname: Cooper
authors.forename: Hedy
authors.initials: H
authors.lastname: Teppler
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Eron
authors.forename: Jose M
authors.initials: JM
authors.lastname: Gatell
authors.forename: Princy N
authors.initials: PN
authors.lastname: Kumar
authors.forename: Jurgen K
authors.initials: JK
authors.lastname: Rockstroh
authors.forename: Mauro
authors.initials: M
authors.lastname: Schechter
authors.forename: Christine
authors.initials: C
authors.lastname: Katlama
authors.forename: Martin
authors.initials: M
authors.lastname: Markowitz
authors.forename: Patrick
authors.initials: P
authors.lastname: Yeni
authors.forename: Mona R
authors.initials: MR
authors.lastname: Loutfy
authors.forename: Adriano
authors.initials: A
authors.lastname: Lazzarin
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Lennox
authors.forename: Bonaventura
authors.initials: B
authors.lastname: Clotet
authors.forename: Jing
authors.initials: J
authors.lastname: Zhao
authors.forename: Hong
authors.initials: H
authors.lastname: Wan
authors.forename: Rand R
authors.initials: RR
authors.lastname: Rhodes
authors.forename: Kim M
authors.initials: KM
authors.lastname: Strohmaier
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Barnard
authors.forename: Robin D
authors.initials: RD
authors.lastname: Isaacs
authors.forename: Bach-Yen T
authors.initials: BY
authors.lastname: Nguyen
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004311:Double-Blind Method; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011760:Pyrrolidinones / Q000009:adverse effects / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D000068898:Raltegravir Potassium; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D011760:Pyrrolidinones; D012367:RNA, Viral; D000068898:Raltegravir Potassium